Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB Announces Third Research Collaboration with Harvard University

Published: Wednesday, October 10, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
New Research Alliance project to focus on human microbiome to develop new therapeutic applications in immunology.

UCB has announced that it has launched a third collaborative research project with Harvard that builds upon the innovative Research Alliance they both signed in 2011.

The third research project named ‘Mining the Human Microbiome” will be headed by Christophe Benoist, M.D., Ph.D., Dennis Kasper, M.D., and Diane Mathis, Ph.D., all Professors in the Division of Immunology in the Department of Microbiology and Immunobiology at Harvard Medical School.

The team will be studying the human microbiome in the intestine, classifying new species in studying their impact on the immune system in order to identify new drugs for preventing or treating immunological diseases.

UCB will provide up to $4.5 million over three years to fund the project.

A microbiome is the totality of microbes, their genetic elements and environmental interactions in a particular environment. Adult humans contain, on average, some 100 trillion bacteria in their intestines alone.

These bacteria are believed to be central to their host’s well-being while heavily influencing the immune system.

The Harvard investigators plan to systematically mine the human microbiome to look for new immunomodulatory molecules in the intestine with potential therapeutic applications.

In order to do so, their labs have designed an interdisciplinary project using recent technological advances in next generation sequencing, whole-genome and single molecule transcript profiling and polychromatic flow cytometry.

“We hope this project will fundamentally shift the paradigm of drug development for immunological diseases, exploiting naturally occurring molecules evolutionarily designed to thwart or harness the immune system,” said the Harvard investigators.

“If found, these molecules would be of enormous potential for probing immune system function, therapeutic application and as a preventative therapy.”

“We are pleased to enter into this, our third innovative collaboration with UCB, which once again couples leaders in academia and industry to drive translation and advance frontier research from the lab to the clinic,” said Isaac T. Kohlberg, Harvard’s Chief Technology Development Officer and head of its Office of Technology Development.

Kohlberg continued, "Harvard's collaboration with UCB is a model of how universities can work with industry to advance the progress of medicine and serve the public interest, which is fundamental to Harvard’s core mission".

“This is the third collaboration we have initiated with Harvard in the last 18 months. Our continued alliance with this renowned institution is testimony to our belief in Harvard’s excellence in scientific research and in the strength of our open innovation model,” said Ismail Kola, President of UCB NewMedicines, UCB’s research and early development division.

Kola continued, “Microbiome is one of modern science’s most exciting fields of research and we are confident that this new collaboration will benefit patients by enabling us to meet unmet health care needs in immunology.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB and Sanofi Partner for Innovation in Immune-Mediated Diseases
Goal is to identify novel small molecule therapies to address a wide range of immune-mediated diseases.
Friday, March 14, 2014
Multimillion Pound Investment in UK Life Sciences Research and Development
UCB invests over £3 million in new bespoke cutting-edge robotic platform for UK R&D HQ.
Wednesday, December 11, 2013
UCB Receives CHMP Positive Opinion for Cimzia in Active PsA
Positive opinion is supported by data from the RAPID™-PsA study.
Monday, October 28, 2013
Vectura and UCB to Collaborate and Share Expertise in Severe Inflammatory
Collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory.
Tuesday, October 01, 2013
UCB to Showcase Immunology Portfolio at EULAR 2012
Data to be presented on certolizumab pegol, epratuzumab and CDP7851/AMG 785.
Thursday, July 05, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!